Login to Your Account

Clovis awaiting credit in ovarian as Lynparza gains; PARP's tomorrow to Tesaro?

By Randy Osborne
Staff Writer

Friday, August 19, 2016

Clovis Oncology Inc.'s publicly known showing with oral PARP inhibitor rucaparib in advanced ovarian cancer turned up in platinum-sensitive patients, which makes comparisons tough with Astrazeneca plc's same-class Lynparza.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription